| Soluble biomarkers of osteoporosis and osteoarthritis, from pathway mapping to clinical trials: an update EE Nagy, C Nagy-Finna, H Popoviciu, B Kovács Clinical interventions in aging, 501-518, 2020 | 40 | 2020 |
| P53 protein as a survival biomarker in myelodysplastic syndromes: immunohistochemical morphometric study EE Nagy, C Finna, S Demian, L Chira, E Horvath Farmacia 64, 104-11, 2016 | 1 | 2016 |
| The grade of neoangiogenesis and the bone marrow blast count predict leukemic transformation-free survival in myelodysplastic syndromes H Emőke, F Csilla, D Smaranda, N Előd-Ernő Revista Romana de Medicina de Laborator 24 (2), 228-231, 2016 | | 2016 |
| p53 protein as useful immunohistochemical marker for predicting leukemic transformation of the myelodysplastic syndrome E Horvath, B Dorcioman, E Molnar, S Demian, ML Turcu, L Chira, ... VIRCHOWS ARCHIV 467, S198-S198, 2015 | | 2015 |
